Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
verpasep caltespen
- Development stage
- Phase 2
- Lead developer
- Stressgen Biotechnologies
- Modality
- Vaccines & Immunotherapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Topical
01
Overview
Verpasep caltespen is a recombinant fusion protein vaccine designed to treat diseases caused by human papillomavirus (HPV), particularly HPV type 16. It consists of the Mycobacterium bovis heat shock protein 65 (Hsp65) covalently linked to the E7 early protein of HPV16. The Hsp65 component serves as an adjuvant and carrier, enhancing the uptake and processing of the E7 antigen by antigen-presenting cells to stimulate a robust CD8+ T-cell mediated immune response against HPV-infected cells. Originally developed by Stressgen Biotechnologies, the agent was investigated in clinical trials for cervical intraepithelial neoplasia (CIN), recurrent respiratory papillomatosis (RRP), and anal intraepithelial neoplasia (AIN). Despite showing promise in early studies, development was largely discontinued after failing to meet primary endpoints in late-stage trials.
- Other names
- verpasep caltespenHspE7 fusion proteinHspE-7 fusion proteinHspE 7 fusion proteinMycobacterium bovis Hsp65-HPV16 E7 fusion protein
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on verpasep caltespen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on verpasep caltespen.